Avanos Medical Stock Price, News & Analysis

Avanos Medical reported a 9% increase in net sales for Q1 2022, totaling $197 million compared to last year. Net income rose to $6 million from a $8 million loss, with adjusted earnings per share at $0.26. The recent acquisition of OrthogenRx contributed positively, and gross margins improved to 54% despite ongoing economic challenges. The company anticipates annual sales between $830 million and $850 million, with adjusted EPS projected at $1.55 to $1.75.

Avanos Medical, Inc. (NYSE: AVNS) will hold a conference call on May 4, 2022, at 9 a.m. ET to discuss its first-quarter 2022 financial results and business highlights. A news release will precede the call, detailing the results. The call will be hosted by CEO Joe Woody and CFO Michael Greiner. Interested parties can join the live call by dialing 877-240-5772 in the U.S. or access the webcast via the Avanos Medical website. A replay will be available later the same day.

Avanos Medical (NYSE: AVNS) will participate in an analyst-led fireside chat at the KeyBanc 2022 Life Sciences & MedTech Investor Forum on March 22, 2022, at approximately 9:45 a.m. ET. CEO Joe Woody and CFO Michael Greiner will present insights into the company's operations and growth strategies. A webcast of the presentation will be available on the Investors section of the Avanos Medical website. The company, headquartered in Alpharetta, Georgia, aims to deliver innovative medical device solutions to enhance patient recovery.

Avanos Medical reported a strong performance for Q4 and full-year 2021 despite COVID-19 challenges. Q4 net sales rose 5% to $193 million, with full-year sales increasing 4% to $745 million. The company achieved a diluted EPS of $0.21 in Q4, compared to a loss last year, and adjusted EPS rose to $0.46. Free cash flow improved significantly, totaling $66 million for 2021. The acquisition of OrthogenRx was completed, enhancing its market presence. For 2022, Avanos expects net sales between $830 million and $850 million, amid ongoing supply chain challenges.

Avanos Medical, Inc. (NYSE: AVNS) will hold a conference call on Feb. 23, 2022, at 9 a.m. ET, to discuss its fourth quarter and full year 2021 financial results. A news release with these results will be issued before the market opens on that day. The call will be led by CEO Joe Woody and CFO Michael Greiner. Participants can access the call by dialing 877-240-5772 in the U.S., with a webcast available through the company’s investor website. A replay will be accessible later that day and for one week following the call.

Avanos Medical (NYSE: AVNS) announced that CEO Joe Woody will present at the 40th Annual J.P. Morgan Healthcare Conference on Jan. 11, 2022, at 10:30 a.m. ET. The presentation will be available via webcast on the Investors section of Avanos' website and will be archived there for later access. Avanos Medical, based in Alpharetta, Georgia, focuses on developing breakthrough medical devices aimed at improving patient outcomes and reducing opioid use during recovery from surgery. For more details, visit www.avanos.com.

Avanos Medical has announced a share repurchase program, allowing the company to buy back up to $30 million of its common stock over a twelve-month period. This initiative, approved by the Board of Directors, aims to enhance shareholder value using existing cash or future cash flows. The buyback will be executed under a Rule 10b5-1 plan that sets specific price, volume, and timing restrictions. CEO Joe Woody expressed confidence in the company's strategy and financial health, emphasizing the prudent investment in the company's stock.

Avanos Medical (NYSE: AVNS) has announced an agreement to acquire OrthogenRx, an innovator in viscosupplementation therapies for knee osteoarthritis (OA) treatment, for $160 million. This includes $130 million in cash and up to $30 million contingent on performance milestones. The acquisition is projected to contribute approximately $65 million in revenue in 2022, enhancing Avanos' chronic pain portfolio and expanding its market presence in a $1 billion U.S. OA treatment sector. The acquisition is expected to close in Q1 2022, pending regulatory approvals.

Avanos Medical, Inc. (NYSE: AVNS) has launched the PainBlock Pro app, designed for real-time patient recovery tracking post-surgery. The app collects patient-reported outcomes (PROs) via daily surveys for up to 10 days, helping providers tailor pain management plans based on pain levels and opioid use. It also offers patients easy access to FAQs and educational resources. Bill Haydon, Senior VP at Avanos, emphasized the app's role in enhancing patient-provider interaction and recovery insights.